What one share of REGENXBIO holds
We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease.
REGENXBIO’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.34 |
|---|---|
| Profit | −$3.77 |
| Capex (buildings and equipment) | $0.06 |
| Free cash flow | −$4.79 |
| Cash and investments | $1.95 |
| Book value | $1.32 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | $2.62 | −$2.50 | — | — | — | −$6.00 |
| 2014 | $2.32 | −$1.82 | — | — | — | −$6.92 |
| 2015 | $0.83 | −$2.59 | $0.06 | −$2.51 | — | — |
| 2016 | $0.17 | −$2.38 | $0.31 | −$2.15 | — | $6.11 |
| 2017 | $0.35 | −$2.45 | $0.24 | −$2.18 | — | $5.85 |
| 2018 | $5.96 | $2.73 | $0.36 | $2.49 | — | $14.09 |
| 2019 | $0.96 | −$2.58 | $0.32 | −$3.25 | — | $12.17 |
| 2020 | $4.15 | −$2.98 | $0.72 | −$2.17 | — | $10.08 |
| 2021 | $10.71 | $2.91 | $1.92 | $3.07 | — | $17.84 |
| 2022 | $2.61 | −$6.50 | $0.71 | −$5.52 | — | $11.92 |
| 2023 | $2.06 | −$6.02 | $0.23 | −$5.22 | — | $7.08 |
| 2024 | $1.68 | −$4.59 | $0.05 | −$3.55 | — | $5.24 |
| 2025 | $3.30 | −$3.76 | $0.05 | −$2.45 | — | $2.02 |
Common questions about REGENXBIO
How much does one share of REGENXBIO earn?
Over the last 12 months, REGENXBIO lost $3.77 for each share on $3.34 of sales.
Does REGENXBIO pay a dividend?
REGENXBIO didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is REGENXBIO’s book value per share?
REGENXBIO’s book value is $1.32 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of REGENXBIO have?
Each share of REGENXBIO has $1.95 of cash and investments, as of June 30, 2026.
What is REGENXBIO’s free cash flow per share?
−$4.79 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has REGENXBIO bought back shares?
REGENXBIO’s share count rose about 2123% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.